<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Moria &#8211; Alchimia</title>
	<atom:link href="https://alchimiasrl.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://alchimiasrl.com/en/</link>
	<description>Your ideas, our solutions</description>
	<lastBuildDate>Thu, 08 Jun 2023 12:40:15 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://alchimiasrl.com/wp-content/uploads/2020/03/cropped-Icon-per-sito-32x32.jpg</url>
	<title>Moria &#8211; Alchimia</title>
	<link>https://alchimiasrl.com/en/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Clinical outcomes of long-term corneas preserved frozen in Eusol-C used in emergency tectonic grafts</title>
		<link>https://alchimiasrl.com/clinical-outcomes-of-long-term-corneas-preserved-frozen-in-eusol-c-used-in-emergency-tectonic-grafts/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 08 Jun 2023 11:29:44 +0000</pubDate>
				<category><![CDATA[Corneal storage at 4°C]]></category>
		<category><![CDATA[Eusol-C]]></category>
		<category><![CDATA[Eye Banking]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22809</guid>

					<description><![CDATA[<p>Year: 2022 Authors: Burgos-Blasco B.; Vidal-Villegas B.; Collado-Vincueria I.; Soria-García A. M.; Cuiña-Sardiña R.; Mendez-Fernandez R.; Diaz-Valle D.; Ariño-Gutierez M.     Cell Tissue Bank doi.org/10.1007/s10561-022-10037-1 Online version This is a: Publication   To report the clinical results on the use of corneas frozen in Eusol-C as tectonic corneal grafts. Retrospective review of medical records of patients who  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/clinical-outcomes-of-long-term-corneas-preserved-frozen-in-eusol-c-used-in-emergency-tectonic-grafts/">Clinical outcomes of long-term corneas preserved frozen in Eusol-C used in emergency tectonic grafts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-1"><p><strong>Year:</strong> 2022</p>
<p><strong>Authors</strong>: <span style="color: windowtext; text-decoration: none; text-underline: none;">Burgos-Blasco</span> B.; Vidal-Villegas B.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Collado-Vincueria</span> I.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Soria-García</span> A. M.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Cuiña-Sardiña</span> R.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Mendez-Fernandez</span> R.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Diaz-Valle</span> D.; <span style="color: windowtext; text-decoration: none; text-underline: none;">Ariño-Gutierez</span> M.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-2"><p>Cell Tissue Bank<br />
doi.org/10.1007/s10561-022-10037-1<br />
<a href="https://link.springer.com/article/10.1007/s10561-022-10037-1?utm_source=toc&amp;utm_medium=email&amp;utm_campaign=toc_10561_24_2&amp;utm_content=etoc_springer_20230525">Online version</a></p>
</div><div class="fusion-text fusion-text-3"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-4"><p id="Abstract" class="article_abstract-title">To report the clinical results on the use of corneas frozen in Eusol-C as tectonic corneal grafts. Retrospective review of medical records of patients who received frozen corneas as emergency tectonic grafts from 2013 to 2020. Corneas had been stored in Eusol-C preservation media at − 78 °C for a mean time of 6.9 months. Diagnosis, transplant characteristics, microbial culture results, anatomic integrity, epithelial healing, neovascularization, transparency, infection and need for additional surgeries were registered. Fifty corneas were used in 40 patients (mean age 60.5 years, 20 males) with a median follow-up of 27.3 months after surgery. Need for tectonic graft was due to: perforation secondary to immune diseases (6, 12%), neurotrophic ulcer (11, 22%), trauma (3, 6%), corneal infection (11, 22%), chronic disorders of the ocular surface (9, 18%) and previous corneal graft failure (10, 22%). Mean size of grafts was 5.6 mm and 36 cases (72%) also received an amniotic membrane graft. Thirty-eight corneas achieved epithelization (76%), 25 (50%) were clear and 19 (38%) developed neovascularization. None of the corneas were rejected. Seventeen corneas (34%) failed: 7 (14%) due to reactivation of baseline disease and 10 (20%) due to primary graft failure. Four corneas (8%) had positive microbial cultures suggestive of contamination and 2 (4%) developed a cornea abscess non-related to a positive microbial culture. Long-term preservation of donor corneas in Eusol-C at − 78 °C is a viable technique to meet the needs of emergency grafts with minimal equipment.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/clinical-outcomes-of-long-term-corneas-preserved-frozen-in-eusol-c-used-in-emergency-tectonic-grafts/">Clinical outcomes of long-term corneas preserved frozen in Eusol-C used in emergency tectonic grafts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Porcine cornea ex vivo model as an alternative to human donor tissues for investigating new preservation conditions</title>
		<link>https://alchimiasrl.com/porcine-cornea-ex-vivo-model-as-an-alternative-to-human-donor-tissues-for-investigating-new-preservation-conditions/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Fri, 03 Mar 2023 13:50:05 +0000</pubDate>
				<category><![CDATA[Corneal storage at 31°C]]></category>
		<category><![CDATA[Corneal storage at 4°C]]></category>
		<category><![CDATA[Eusol-C]]></category>
		<category><![CDATA[Eye Banking]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<category><![CDATA[TISSUE-C]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22785</guid>

					<description><![CDATA[<p>Year: 2023, EEBA Authors: Rodella U.; Bosio L.; Ferrari S.; Gatto C.; Giurgola L.; Rossi O.; Ciciliot S.; Ragazzi E.; Ponzin D.; D’Amato Tóthová J.   PURPOSE Considering the growing shortage of corneal tissues for research, the present study aimed to develop and optimize a porcine cornea model with qualitative features comparable to  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/porcine-cornea-ex-vivo-model-as-an-alternative-to-human-donor-tissues-for-investigating-new-preservation-conditions/">Porcine cornea ex vivo model as an alternative to human donor tissues for investigating new preservation conditions</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-1 hover-type-none"><img decoding="async" width="200" height="200" title="EEBA logo" src="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png" alt class="img-responsive wp-image-12279" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-5"><p><strong>Year:</strong> 2023, EEBA</p>
<p><strong>Authors: </strong>Rodella U.; Bosio L.; Ferrari S.; Gatto C.; Giurgola L.; Rossi O.; Ciciliot S.; Ragazzi E.; Ponzin D.; D’Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-6"><p><strong>PURPOSE<br />
</strong>Considering the growing shortage of corneal tissues for research, the present study aimed to develop and optimize a porcine cornea model with qualitative features comparable to those of human tissues.</p>
<p><strong>METHODS</strong><br />
A new decontamination procedure of porcine eye bulbs was set up and its efficacy as well as endothelial mortality were evaluated. Human corneas unsuitable for transplant and porcine corneas were then compared after storage under hypothermic (4–8°C, Eusol-C, AL.CHI.MI.A. S.R.L) or organ-culture (31–35°C, Tissue-C, AL.CHI.MI.A. S.R.L) storage conditions for 14 days. A new method, based on the semi-automatic analysis of Trypan-blue stained endothelial areas by Fiji software, was developed to quantify the whole endothelium viability.<br />
Corneas were assessed for central corneal thickness (CCT), corneal transparency, endothelial morphology, and endothelial cell density (ECD) at days 0, 7, and 14 of storage. Portions of lamellar tissues consisting of Descemet’s membrane and endothelial cells were prepared for histological investigations.</p>
<p><strong>RESULTS</strong><br />
The new decontamination procedure of porcine eye bulbs resulted in 18% versus 89% (&#8220;no decontamination&#8221; control) of corneas still contaminated after 28 days of storage at 31°C. The decontamination protocol did not affect endothelium viability, as assessed by the new Fijibased method. ECD (porcine: 3156 ± 144 cells/mm2; human: 2287 ± 152 cells/mm2), CCT (porcine: 1073 ± 151 μm; human: 581 ± 39 μm), transparency (porcine: 88.6 ± 11.0 %; human: 76.3 ± 5.4 %), and morphology score (porcine: 4.0 ± 0.0; human: 3.2 ± 0.4) measured in the porcine cornea at day 0 were significantly higher than in human corneas. Nonetheless, the qualitative parameters of porcine and human corneas showed comparable trends during the storage under hypothermic (4–8°C) and organ-culture (31–35°C) conditions for 14 days.</p>
<p><strong>CONCLUSIONS</strong><br />
The presented porcine cornea model represents a reliable and alternative model to human donor tissues for preliminary investigations and can be used for testing new media, substances, drugs, or preservation conditions and their impact on corneal tissue quality and safety. Furthermore, the quantitative method to assess whole endothelium mortality can be implemented at eye banks for the evaluation of corneas intended for transplantation.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/porcine-cornea-ex-vivo-model-as-an-alternative-to-human-donor-tissues-for-investigating-new-preservation-conditions/">Porcine cornea ex vivo model as an alternative to human donor tissues for investigating new preservation conditions</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Descemet’s membrane endothelial keratoplasty (DMEK) graft preparation in porcine cornea</title>
		<link>https://alchimiasrl.com/descemets-membrane-endothelial-keratoplasty-dmek-graft-preparation-in-porcine-cornea/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Fri, 03 Mar 2023 13:39:24 +0000</pubDate>
				<category><![CDATA[Corneal storage at 4°C]]></category>
		<category><![CDATA[Eusol-C]]></category>
		<category><![CDATA[Eye Banking]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22775</guid>

					<description><![CDATA[<p>Year: 2023, EEBA Authors: Giurgola L.; Gatto C.; Rodella U.; D’Amato Tóthová J.   PURPOSE Descemet’s membrane endothelial keratoplasty (DMEK) is a frequently used treatment option for patients with corneal endothelial dysfunction. The aim of this study was to set up a method to prepare porcine DMEK grafts and to simulate DMEK surgery  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/descemets-membrane-endothelial-keratoplasty-dmek-graft-preparation-in-porcine-cornea/">Descemet’s membrane endothelial keratoplasty (DMEK) graft preparation in porcine cornea</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-3 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-2 hover-type-none"><img decoding="async" width="200" height="200" title="EEBA logo" src="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png" alt class="img-responsive wp-image-12279" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-7"><p><strong>Year:</strong> 2023, EEBA</p>
<p><strong>Authors: </strong>Giurgola L.; Gatto C.; Rodella U.; D’Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-8"><p><strong>PURPOSE</strong><br />
Descemet’s membrane endothelial keratoplasty (DMEK) is a frequently used treatment option for patients with corneal endothelial dysfunction.<br />
The aim of this study was to set up a method to prepare porcine DMEK grafts and to simulate DMEK surgery in porcine eye bulbs in order to<br />
establish an ex-vivo-model for laboratory investigations on DMEK surgery conditions.</p>
<p><strong>METHODS</strong><br />
Ten (n=10) porcine eye bulbs from domestic pigs (Sus scrofa domestica), between 6 and 8 months old, were recovered at a local slaughterhouse, transported on ice and processed within 2 h after death. Porcine eye bulbs were decontaminated by immersion in 10 mL of 5% povidone-iodine and corneas were dissected under aseptic conditions, leaving approximately 2 mm of the scleral rim. DMEK grafts were prepared by means of mechanical stripping technique using specific surgical instruments for DMEK (Moria, France) on fresh corneas (n=2) and on corneas stored in Eusol-C (AL.CHI.MI.A. Srl, Italy) at 4°C for 7 days (n=4) and for 14 days (n=4). Endothelial cell (EC) density was compared before DMEK-preparation (specular and light microscopy on trypan blue stained tissues) and after DMEK-preparation (fluorescence microscopy on Calcein-AM stained tissues). DMEK graft injection was simulated in anterior chamber of fresh porcine eye bulbs.</p>
<p><strong>RESULTS</strong><br />
The porcine DMEK grafts preparation resulted to be more challenging compared to human DMEK grafts. Despite similarity between human and porcine corneas, porcine Descemet membrane (DM) firmly adheres to the underlying stroma. DMEK grafts preparation was not successful at day 0; DMEK preparation was possible by mechanical stripping technique on corneas stored in Eusol-C for 7 and 14 days obtaining naturally rolled endo-out porcine DMEK grafts. An EC mortality increase up to 20% was observed on DMEK graft compared to initial whole corneal tissue. DMEK roll injection was successfully simulated in anterior chamber of the porcine eye bulb.</p>
<p><strong>CONCLUSIONS</strong><br />
Naturally rolled DMEK endo-out grafts were successfully prepared by mechanical stripping technique on porcine corneal tissues stored in Eusol-C at 4°C (up to 14 days). DMEK Surgery including the tissue injection in anterior chamber could be simulated. Further studies will be performed to improve ex-vivo-porcine DMEK surgery model.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/descemets-membrane-endothelial-keratoplasty-dmek-graft-preparation-in-porcine-cornea/">Descemet’s membrane endothelial keratoplasty (DMEK) graft preparation in porcine cornea</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Assessment of performance and safety of Corneal Chamber hypotherm ic storage and pss-l corneal rinsing in human and porcine corneas</title>
		<link>https://alchimiasrl.com/assessment-of-performance-and-safety-of-corneal-chamber-hypotherm-ic-storage-and-pss-l-corneal-rinsing-in-human-and-porcine-corneas/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Fri, 03 Mar 2023 13:21:37 +0000</pubDate>
				<category><![CDATA[Corneal chamber]]></category>
		<category><![CDATA[Corneal storage at 4°C]]></category>
		<category><![CDATA[Eye Banking]]></category>
		<category><![CDATA[Globe & corneal rinsing]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[PSS-L]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22762</guid>

					<description><![CDATA[<p>Year: 2023, EEBA Authors: Giurgola L.; Rodella U.; Gatto C.; Rossi O.; D’Amato Tóthová J.   PURPOSE To prove the safety and performance of the hypothermic corneal storage medium Corneal Chamber, containing Eusol-C solution (AL.CHI.MI.A. S.r.l.) and of the rinsing solution PSS-L (AL.CHI.MI.A. S.r.l.) in support to the new CE certification process in  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/assessment-of-performance-and-safety-of-corneal-chamber-hypotherm-ic-storage-and-pss-l-corneal-rinsing-in-human-and-porcine-corneas/">Assessment of performance and safety of Corneal Chamber hypotherm ic storage and pss-l corneal rinsing in human and porcine corneas</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-4 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-3 hover-type-none"><img decoding="async" width="200" height="200" title="EEBA logo" src="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png" alt class="img-responsive wp-image-12279" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/eeba-logo.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-9"><p><strong>Year:</strong> 2023, EEBA</p>
<p><strong>Authors: </strong>Giurgola L.; Rodella U.; Gatto C.; Rossi O.; D’Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-10"><p><strong>PURPOSE</strong><br />
To prove the safety and performance of the hypothermic corneal storage medium Corneal Chamber, containing Eusol-C solution (AL.CHI.MI.A. S.r.l.) and of the rinsing solution PSS-L (AL.CHI.MI.A. S.r.l.) in support to the new CE certification process in accordance to the EU 2017/745 Medical Device Regulation.</p>
<p><strong>METHODS</strong><br />
Fifteen (n=15) human donor corneas unsuitable for transplantation and n=11 porcine corneas were evaluated for the following quality parameters: ECD, HEX%, CV%, endothelial morphology, endothelial mortality and transparency at day 0 and after 14±1 days (day 14) of storage in Corneal Chamber at 2-8°C. Then, corneas were rinsed in PSS-L for 1’ at room temperature (RT) and the same parameters were assessed Post Rinsing (Day 14PR). In order to evaluate the antimicrobial carryover after the corneal storage in Corneal Chamber(14 days at 4°C), gentamicin sulphate was quantified in human and porcine corneas homogenates by UHPLC.</p>
<p><strong>RESULTS</strong><br />
Human and porcine corneas stored in Corneal Chamber at 2-8°C for 14 days showed a good overall quality of the tissue according to quality parameters evaluated. In particular, mean ECD, HEX% and CV% did not show statistically significant changes at the end of storage and endothelial mortality increased of 3.1±3.3 % in human corneas and 7.8±3.5 % in porcine corneas. Slight variations in endothelial morphology score and corneal transparency were observed. Rinsing with PSS-L did not negatively affect the quality parameters evaluated before and after rinsing and gentamicin sulfate residues were completely removed.</p>
<p><strong>CONCLUSIONS</strong><br />
The storage of corneal tissues in Corneal Chamber at 2-8°C for 14 days and the corneal rinse with 30 ml of PSS-L at RT for 1 min are safe and<br />
effective procedures allowing the preservation of the corneal quality parameters including ECD, endothelial mortality, endothelial morphology,<br />
HEX%, CV%, and corneal transparency and the elimination of gentamicin sulfate from the tissues before transplantation.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/assessment-of-performance-and-safety-of-corneal-chamber-hypotherm-ic-storage-and-pss-l-corneal-rinsing-in-human-and-porcine-corneas/">Assessment of performance and safety of Corneal Chamber hypotherm ic storage and pss-l corneal rinsing in human and porcine corneas</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</title>
		<link>https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 29 Dec 2022 16:58:45 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22744</guid>

					<description><![CDATA[<p>Year: 2022 Authors: Gatto C.; Ruzza P.; Giurgola L.; Honisch C.; Rossi O.; Romano M. R.; Ragazzi E.; D'Amato Tóthová J.     ACS Omega Journal doi/10.1021/acsomega.2c04697 Online version This is a: Publication   The purpose of this study is to compare the in vitro cytotoxicity tests according to the ISO  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/">Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-5 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-11"><p><strong>Year:</strong> 2022</p>
<p><strong>Authors</strong>: <span class="hlFld-ContribAuthor">Gatto C.; </span><span class="hlFld-ContribAuthor">Ruzza P.; </span><span class="hlFld-ContribAuthor">Giurgola L.; </span><span class="hlFld-ContribAuthor">Honisch C.; </span><span class="hlFld-ContribAuthor">Rossi O.; </span><span class="hlFld-ContribAuthor">Romano M. R.; </span><span class="hlFld-ContribAuthor">Ragazzi E.; D&#8217;Amato Tóthová J.</span></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-12"><p><span class="journal-name">ACS Omega Journal</span><br />
doi/10.1021/acsomega.2c04697<br />
<a href="https://pubs.acs.org/doi/10.1021/acsomega.2c04697">Online version</a></p>
</div><div class="fusion-text fusion-text-13"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-14"><p id="Abstract" class="article_abstract-title"><span style="font-size: 16px;">The purpose of this study is to compare the in vitro cytotoxicity tests according to the ISO 10993-5 (2009) standards using direct contact and the test on liquid extracts of compounds previously identified as possible toxic impurities in perfluorocarbon liquids (PFCLs) for use in vitreoretinal surgery. Compounds including perfluorooctanoic acid (PFOA), 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-perfluorooctane (1H-PFO), 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-tridecafluoro-2-methylpentane, 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-octafluorocyclopentane, and 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,3</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-decafluoropentane were analyzed by </span><sup>19</sup><span style="font-size: 16px;">F NMR before and after extraction using an aqueous solution and tested by both the direct contact and liquid extract tests in L929, BALB 3T3, and ARPE-12 cells. The concentration that reduced in vitro cell viability by 30%, the cytotoxicity concentration threshold (CC</span><sub>30</sub><span style="font-size: 16px;">), was determined for each compound. </span><sup>19</sup><span style="font-size: 16px;">F NMR spectroscopy confirmed the immiscibility of perfluoro-</span><i style="font-size: 16px;">n</i><span style="font-size: 16px;">-octane (PFO) and 1H-PFO and the solubility of PFOA with the extraction vehicle. The other samples reacted with the extraction vehicle, releasing fluoride ions. Using the direct contact test, the CC</span><sub>30</sub><span style="font-size: 16px;"> of PFOA, 1H-PFO, 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-tridecafluoro-2-methylpentane, 1</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-octafluorocyclopentane, and 2</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">,3</span><i style="font-size: 16px;">H</i><span style="font-size: 16px;">-decafluoropentane corresponded to 48 124, 50, 14, 8035, and 46 ppm, respectively. The method on liquid extracts did not detect cytotoxicity in three out of five tested compounds, and CC</span><sub>30</sub><span style="font-size: 16px;"> could not be determined. In conclusion, the in vitro cytotoxicity test by direct contact revealed a positive correlation between cell toxicity and the concentration of the tested substance. Conversely, the test on liquid extracts hardly detected the cytotoxicity of toxic impurities in PFCLs. Thus, only the cytotoxicity test by direct contact, according to ISO 10993-5 (2009), is a sensible and reliable method to detect possible cytotoxic impurities in PFCLs to guarantee patient safety.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/comparison-of-perfluorocarbon-liquids-cytotoxicity-tests-direct-contact-versus-the-test-on-liquid-extracts/">Comparison of Perfluorocarbon Liquids Cytotoxicity Tests: Direct Contact Versus the Test on Liquid Extracts</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Corneal Storage Media with Amphotericin-B: Results from a Prospective Laboratory Study  Submitted for Class 2 De Novo 510(k) Premarket Approval</title>
		<link>https://alchimiasrl.com/corneal-storage-media-with-amphotericin-b-results-from-a-prospective-laboratory-study-submitted-for-class-2-de-novo-510k-premarket-approval/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 12 Oct 2022 09:58:08 +0000</pubDate>
				<category><![CDATA[Cornea and Eye Banking Forum]]></category>
		<category><![CDATA[Corneal storage at 4°C]]></category>
		<category><![CDATA[Eye Banking]]></category>
		<category><![CDATA[KERASAVE]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22708</guid>

					<description><![CDATA[<p>Year: 2022, Cornea and Eye Banking Forum Authors: Tran K., PhD Co-authors: Ellison M.S., BA, BS; Straiko M.M.W., PhD; Giurgola L., MSc; Gatto C., MSc; Prof. Ragazzi E., MD; D’Amato Tothova J.   PURPOSE To compare endothelial cell density and morphometry, thickness, and transparency of corneas stored in Kerasave vs. Optisol-GS for 14  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/corneal-storage-media-with-amphotericin-b-results-from-a-prospective-laboratory-study-submitted-for-class-2-de-novo-510k-premarket-approval/">Corneal Storage Media with Amphotericin-B: Results from a Prospective Laboratory Study  Submitted for Class 2 De Novo 510(k) Premarket Approval</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-6 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-4 hover-type-none"><img decoding="async" width="2362" height="2362" title="CEBF 2022_200X200" src="https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1.jpg" alt class="img-responsive wp-image-22722" srcset="https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1-200x200.jpg 200w, https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1-400x400.jpg 400w, https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1-600x600.jpg 600w, https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1-800x800.jpg 800w, https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1-1200x1200.jpg 1200w, https://alchimiasrl.com/wp-content/uploads/2022/10/CEBF-2022_200X200-1.jpg 2362w" sizes="(max-width: 800px) 100vw, 400px" /></span></div></div><div class="fusion-text fusion-text-15"><p><strong>Year:</strong> 2022, Cornea and Eye Banking Forum</p>
<p><strong>Authors</strong>: Tran K., PhD<br />
<strong>Co-authors: </strong>Ellison M.S., BA, BS; Straiko M.M.W., PhD; Giurgola L., MSc; Gatto C., MSc; Prof. Ragazzi E., MD; D’Amato Tothova J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-16"><p><strong>PURPOSE<br />
</strong>To compare endothelial cell density and morphometry, thickness, and transparency of corneas stored in Kerasave vs. Optisol-GS for 14 days.</p>
<p><strong>METHODS<br />
</strong>Mate corneas were recovered into Kerasave or Optisol-GS (27 pairs) and stored at 2-8°C for 14 days.<br />
Endothelial cell density (ECD), hexagonality (HEX), and coefficient of variation (CV) were evaluated by specular microscopy, and central corneal thickness (CCT) was examined by OCT after 1, 3, 7, and 14 days of storage. Corneal transparency was scored using slit-lamp examination at days 1 and 14.</p>
<p><strong>RESULTS</strong><br />
Average ECD, HEX, and CV for the Kerasave (2653±303, 57±4, 36±3) and Optisol-GS (2623±306, 57±5, 36±4) groups were not significantly different at day 1. There was also no difference at any other study timepoints (P&gt;0.05 for all). ECD did not significantly change from day 1 to day 14 in either group (P&gt;0.05), but a statistically significant change in HEX and CV was observed between day 1 and day 14 in both groups (P&lt;0.01). Average CCT measured at day 1 for corneas stored in Kerasave was 622±49 and those stored in Optisol-GS was 580±35 (P&lt;0.01). The difference in CCT measurements was not significant different at day 14 (674±46 v. 647±58, P&gt;0.05). Corneal transparency was not significantly different between the two groups at day 1 or day 14.</p>
<p><strong>CONCLUSION</strong><br />
Endothelial cell density, endothelial morphometry, and corneal transparency were not different in corneas stored in Kerasave or Optisol-GS for 14 days.<br />
Optisol-GS was initially better at thinning the cornea than Kerasave. These results suggest that Kerasave is a viable alternative to Optisol-GS for corneal storage.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/corneal-storage-media-with-amphotericin-b-results-from-a-prospective-laboratory-study-submitted-for-class-2-de-novo-510k-premarket-approval/">Corneal Storage Media with Amphotericin-B: Results from a Prospective Laboratory Study  Submitted for Class 2 De Novo 510(k) Premarket Approval</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ALCHIMIA SRL entra en el grupo MORIA</title>
		<link>https://alchimiasrl.com/alchimia-srl-entra-en-el-grupo-moria/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 07 Sep 2022 12:51:31 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/alchimia-srl-has-become-part-of-the-moria-group/</guid>

					<description><![CDATA[<p>7 de Septiembre, 2022  La empresa italiana ALCHIMIA SRL, uno de los principales fabricantes europeos de dispositivos médicos para cirugía oftálmica y banca de tejidos humanos, se ha convertido en parte del grupo Moria SA. "Una sinergia en nombre de la máxima calidad de la que siempre hemos sido promotores y que  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-entra-en-el-grupo-moria/">ALCHIMIA SRL entra en el grupo MORIA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-7 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1144px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-margin-top-large:0px;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:5.76%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.88%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-17"><p style="text-align: left;"><em>7 de Septiembre, 2022</em></p>
</div><div class="fusion-text fusion-text-18"><p>La empresa italiana ALCHIMIA SRL, uno de los principales fabricantes europeos de dispositivos médicos para cirugía oftálmica y banca de tejidos humanos, se ha convertido en parte del grupo Moria SA.</p>
<p>&#8220;Una sinergia en nombre de la <strong>máxima calidad</strong> de la que siempre hemos sido promotores y que se funde con la historia de <strong>excelencia</strong> y <strong>solidez</strong> del Grupo Moria SA. Estamos emocionados por este nuevo viaje que nos llevará a delinear nuevos horizontes en el campo de la oftalmología&#8221;, dice Paolo Signori, vicepresidente de ALCHIMIA SRL.</p>
<p><strong>Sobre Moria </strong></p>
<p>Fundada en Francia en 1820, MORIA es un grupo francés líder en el campo de los dispositivos quirúrgicos oftálmicos reconocido por su <em>know-how</em> en la fabricación de instrumentos para microcirugía oftálmica, equipos para cirugía refractiva y cirugía de trasplante.</p>
</div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-entra-en-el-grupo-moria/">ALCHIMIA SRL entra en el grupo MORIA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ALCHIMIA SRL entra a far parte del gruppo MORIA</title>
		<link>https://alchimiasrl.com/alchimia-srl-entra-a-far-parte-del-gruppo-moria/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 07 Sep 2022 12:51:31 +0000</pubDate>
				<category><![CDATA[News ITA]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/alchimia-srl-has-become-part-of-the-moria-group/</guid>

					<description><![CDATA[<p>7 Settembre, 2022  La compagnia italiana ALCHIMIA SRL, uno dei principali produttori di dispositivi medici per la chirurgia oftalmica e per le banche dei tessuti, è entrata a far parte del gruppo Moria SA. "Una sinergia all’insegna della massima qualità di cui da sempre siamo promotori e che si fonde con la  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-entra-a-far-parte-del-gruppo-moria/">ALCHIMIA SRL entra a far parte del gruppo MORIA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-8 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1144px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-margin-top-large:0px;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:5.76%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-15 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.88%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-19"><p style="text-align: left;"><em>7 Settembre, 2022</em></p>
</div><div class="fusion-text fusion-text-20"><p>La compagnia italiana ALCHIMIA SRL, uno dei principali produttori di dispositivi medici per la chirurgia oftalmica e per le banche dei tessuti, è entrata a far parte del gruppo Moria SA.</p>
<p>&#8220;Una sinergia all’insegna della <strong>massima qualità</strong> di cui da sempre siamo promotori e che si fonde con la storia di <strong>eccellenza</strong> e <strong>solidità</strong> del Gruppo Moria SA. Siamo entusiasti di questo nuovo viaggio che ci porterà a delineare nuovi orizzonti nel campo dell’oftalmologia”, conferma Paolo Signori, vicepresidente di ALCHIMIA SRL.</p>
<p><strong>Chi è Moria</strong></p>
<p>Fondata in Francia nel 1820, MORIA è uno dei principali gruppi francesi nel settore dei dispositivi chirurgici oftalmici riconosciuta per il <em>know-how</em> nella produzione di strumenti per la microchirurgia oftalmica, attrezzature per la chirurgia refrattiva e la chirurgia dei trapianti.</p>
</div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-entra-a-far-parte-del-gruppo-moria/">ALCHIMIA SRL entra a far parte del gruppo MORIA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ALCHIMIA SRL has become part of the MORIA Group</title>
		<link>https://alchimiasrl.com/alchimia-srl-has-become-part-of-the-moria-group/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 07 Sep 2022 12:51:31 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22467</guid>

					<description><![CDATA[<p>September 07, 2022  The Italian company ALCHIMIA SRL, one of the leading European manufacturers of medical devices for ophthalmic surgery and human tissue banking, has become part of the Moria SA group. "A synergy in the name of maximum quality of which we have always been promoters and which merges to the  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-has-become-part-of-the-moria-group/">ALCHIMIA SRL has become part of the MORIA Group</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-9 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1144px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-16 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-margin-top-large:0px;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:5.76%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-17 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.88%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-21"><p style="text-align: left;"><em>September 07, 2022</em></p>
</div><div class="fusion-text fusion-text-22"><p>The Italian company ALCHIMIA SRL, one of the leading European manufacturers of medical devices for ophthalmic surgery and human tissue banking, has become part of the Moria SA group.</p>
<p>&#8220;A synergy in the name of <strong>maximum quality</strong> of which we have always been promoters and which merges to the history of <strong>excellence</strong> and <strong>solidity</strong> of the Moria SA Group. We are excited for this new journey that will lead us to outline new horizons in the field of ophthalmology&#8221;, says Paolo Signori, vice president of ALCHIMIA SRL.</p>
<p><strong>About Moria</strong></p>
<p>Founded in France in 1820, MORIA is a leading French group in the field of ophthalmic surgical devices recognized for its <em>know-how</em> in the manufacture of instruments for ophthalmic microsurgery, equipment for refractive surgery and transplant surgery.</p>
</div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/alchimia-srl-has-become-part-of-the-moria-group/">ALCHIMIA SRL has become part of the MORIA Group</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>KERASAVE obtuvo el registro De Novo de la FDA</title>
		<link>https://alchimiasrl.com/kerasave-obtuvo-el-registro-de-novo-de-la-fda/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Tue, 10 May 2022 09:04:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=22115</guid>

					<description><![CDATA[<p>Más información sobre kerasave   Estamos orgullosos de anunciar que KERASAVE, el medio totalmente sintético y antifúngico de Alchimia, para la conservación de la córnea a 4°C hasta 14 días, ha obtenido el registro De Novo de la Food and Drug Administration (FDA). El resultado construido por el equipo Alchimia es el fruto  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/kerasave-obtuvo-el-registro-de-novo-de-la-fda/">KERASAVE obtuvo el registro De Novo de la FDA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-10 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-18 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element in-legacy-container" style="--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><span class=" fusion-imageframe imageframe-none imageframe-5 hover-type-none"><img decoding="async" width="1600" height="1440" title="S_COMP_KER 002_Scatola+prodottoALL_RGB" src="https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1.jpg" alt class="img-responsive wp-image-22161" srcset="https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1-200x180.jpg 200w, https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1-400x360.jpg 400w, https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1-600x540.jpg 600w, https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1-800x720.jpg 800w, https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1-1200x1080.jpg 1200w, https://alchimiasrl.com/wp-content/uploads/2022/05/S_COMP_KER-002_ScatolaprodottoALL_RGB-1.jpg 1600w" sizes="(max-width: 800px) 100vw, 400px" /></span></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;margin-bottom:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-aligncenter"><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-1 fusion-button-default-span fusion-button-default-type" style="--button-border-radius-top-left:0;--button-border-radius-top-right:0;--button-border-radius-bottom-right:0;--button-border-radius-bottom-left:0;" target="_self" href="https://alchimiasrl.com/it/banche-dei-tessuti-umani/banche-degli-occhi/conservazione-della-cornea-a-4c/kerasave/"><span class="fusion-button-text awb-button__text awb-button__text--default">Más información sobre kerasave</span></a></div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-19 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-23"><p>Estamos orgullosos de anunciar que <a href="https://alchimiasrl.com/es/banco-de-tejidos-humanos/los-bancos-de-ojos/conservacion-de-la-cornea-a-4c/kerasave/">KERASAVE</a>, el medio totalmente sintético y antifúngico de Alchimia, para la conservación de la córnea a 4°C hasta 14 días, ha obtenido el registro De Novo de la Food and Drug Administration (FDA).</p>
<p>El resultado construido por el equipo Alchimia es el fruto de constantes inversiones en investigación y desarrollo en un sector como los bancos de ojos que necesita dispositivos médicos de altísimo rendimiento, capaces de garantizar seguridad y máxima eficacia.</p>
<p>Ahora que los trasplantes de córnea en el mundo llegan a más de 12 millones de personas en lista de espera, llega la aprobación de la FDA que da luz verde en el mercado estadounidense a un producto, KERASAVE, entre los más completos disponibles hoy en el mercado.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-title title fusion-title-1 fusion-title-text fusion-title-size-one"><h1 class="fusion-title-heading title-heading-left fusion-responsive-typography-calculated" style="margin:0;--fontSize:33;line-height:1.45;"><strong>LA DECISIÓN DE LA FDA</strong></h1><span class="awb-title-spacer"></span><div class="title-sep-container"><div class="title-sep sep- sep-solid" style="border-color:#e0dede;"></div></div></div><div class="fusion-text fusion-text-24"><p>El organismo gubernamental estadounidense ha identificado a KERASAVE como un medio para la conservación de la córnea con conservantes que incluyen antifúngicos.</p>
<p>Dispositivo médico de Clase II con receta médica, KERASAVE se utilizará para conservar temporalmente el tejido corneal humano entre la recolección y el implante.</p>
<p>¿Resultado? KERASAVE está inmediatamente disponible para su uso en los Estados Unidos.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:30px;margin-bottom:30px;width:100%;"><div class="fusion-separator-border sep-shadow" style="--awb-height:20px;--awb-amount:20px;background:radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-webkit-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-moz-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-o-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);"></div></div><div class="fusion-sep-clear"></div><div class="fusion-title title fusion-title-2 fusion-title-text fusion-title-size-one"><h1 class="fusion-title-heading title-heading-left fusion-responsive-typography-calculated" style="margin:0;--fontSize:33;line-height:1.45;"><strong>¿QUÉ SIGNIFICA HABER OBTENIDO UNA CONCESIÓN DE NOVO POR PARTE DE FDA?</strong></h1><span class="awb-title-spacer"></span><div class="title-sep-container"><div class="title-sep sep- sep-solid" style="border-color:#e0dede;"></div></div></div><div class="fusion-text fusion-text-25"><p>El hecho de haber registrado un producto médico De Novo significa que somos los fundadores de una nueva categoría de productos que nunca antes había existido.</p>
<p>Todos lo que querrán registrar un dispositivo médico similar, tendrán que demostrar a la FDA que el dispositivo tiene las mismas características de rendimiento y seguridad que KERASAVE, que se convierte en el modelo de referencia para su categoría.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:30px;margin-bottom:50px;width:100%;"><div class="fusion-separator-border sep-shadow" style="--awb-height:20px;--awb-amount:20px;background:radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-webkit-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-moz-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);background:-o-radial-gradient(ellipse at 50% -50% , #e0dede 0px, rgba(255, 255, 255, 0) 80%) repeat scroll 0 0 rgba(0, 0, 0, 0);"></div></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-26"><h2>Vea el vídeo y descubra cómo utilizar KERASAVE</h2>
</div><div class="fusion-video fusion-youtube" style="--awb-max-width:600px;--awb-max-height:360px;"><div class="video-shortcode"><div class="fluid-width-video-wrapper" style="padding-top:60%;" ><iframe title="YouTube video player 1" src="https://www.youtube.com/embed/WBav6lIY990?wmode=transparent&autoplay=0" width="600" height="360" allowfullscreen allow="autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture;"></iframe></div></div></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:50px;margin-bottom:50px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-27"><p>El resultado del registro De Novo de KERASAVE está disponible directamente en el sitio web de la FDA<br />
<a href="https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries">https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:20px;margin-bottom:20px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-28"><p>Síganos en nuestras redes sociales para ver los entresijos de la producción de KERASAVE</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/kerasave-obtuvo-el-registro-de-novo-de-la-fda/">KERASAVE obtuvo el registro De Novo de la FDA</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
